The TRPV1 vanilloid receptor: A target for therapeutic intervention

被引:14
|
作者
Breitenbucher, JG [1 ]
Chaplan, SR [1 ]
Carruthers, NI [1 ]
机构
[1] Johnson & Johnson Pharmaceut Res & Dev LLC, San Diego, CA 92121 USA
关键词
D O I
10.1016/S0065-7743(05)40012-3
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Capsaicin (1), the active component of hot chili peppers, and related irritant compounds exert their pharmacological effect via activation of an excitatory ion channel expressed on nociceptors [1]. The cellular target for 1 was cloned and characterized from a cDNA from rat sensory neurons in 1997 and named the VR1 receptor [2]. Additional members of the family were subsequently cloned in several laboratories leading to multiple names for the same receptor. This prompted the adoption of the transient receptor potential (TRP) nomenclature whereby the VR1 receptor is now known as the TRPV1 receptor [3]. This family of receptors consist of a large class of ion channels characterized by their permeability to monovalent cations and calcium ions, exhibiting a common structure made up of subunits with six membrane spanning domains [4,5]. The cloning of the rat receptor was quickly followed by the cloning of the human isoform [6] together with the characterization of TRPV1 "knockout" mice by two groups [7,8]. Knockout studies demonstrated that the receptor plays a key role as an integrator of noxious and chemical stimuli that produce pain. The receptor may be activated by heat, low pH, additional vanilloids, including the ultrapotent daphnane diterpenoid resiniferatoxin (RTX) (2), and a range of endogenous mediators encompassing products of the lipoxygenase pathway, bradykinin, and the endocannabinoid anandamide [1,9,10]. Thus numerous activators, often associated with tissue injury or inflammation, appear to operate by reducing the heat threshold of the receptor. © 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:185 / 198
页数:14
相关论文
共 50 条
  • [1] ANANDAMIDE AND THE VANILLOID RECEPTOR (TRPV1)
    Toth, Attila
    Blumberg, Peter M.
    Boczan, Judit
    VITAMINS AND HORMONES: ANANDAMIDE AN ENDOGENOUS CANNABINOID, 2009, 81 : 389 - 419
  • [2] The Vanilloid (Capsaicin) Receptor TRPV1 in Blood Pressure Regulation: A Novel Therapeutic Target in Hypertension?
    Szallasi, Arpad
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (10)
  • [3] IS TRANSIENT RECEPTOR POTENTIAL VANILLOID TYPE 1 (TRPV1) A NEW TARGET FOR CARDIOPROTECTION?
    AL-Mawla, R.
    Paita, L.
    Bidault-Ducreux, S.
    Chouabe, C.
    Durand, A.
    Augeul, L.
    Dupre-Aucouturier, S.
    Bonvallet, R.
    Ovize, M.
    Van Coppenolle, F.
    JOURNAL OF HYPERTENSION, 2016, 34 : E212 - E213
  • [4] Transient Receptor Potential Vanilloid 1 (TRPV1) as a plausible novel therapeutic target for treating neurological complications in ZikaVirus
    Bhandari, Ranjana
    Gupta, Reetrakshi
    Vashishth, Anushka
    Kuhad, Anurag
    MEDICAL HYPOTHESES, 2021, 156
  • [5] TRPV1 (vanilloid receptor, capsaicin receptor) agonists and antagonists
    Appendino, G
    Muñoz, E
    Fiebich, BL
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2003, 13 (12) : 1825 - 1837
  • [6] Uncoupling proton activation of vanilloid receptor TRPV1
    Ryu, Sujung
    Liu, Beiying
    Yao, Jing
    Fu, Qiang
    Qin, Feng
    JOURNAL OF NEUROSCIENCE, 2007, 27 (47): : 12797 - 12807
  • [7] Biochemical pharmacology of the vanilloid receptor TRPV1 - An update
    Cortright, DN
    Szallasi, A
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 2004, 271 (10): : 1814 - 1819
  • [8] Evodiamine functions as an agonist for the vanilloid receptor TRPV1
    Pearce, LV
    Petukhov, PA
    Szabo, T
    Kedei, N
    Bizik, F
    Kozikowski, AP
    Blumberg, PM
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2004, 2 (16) : 2281 - 2286
  • [9] CHARACTERIZATION OF ALCOHOL MODULATION OF VANILLOID RECEPTOR 1 (TRPV1)
    Khan, Nadia
    Howard, Rebecca J.
    Harris, R. Adron
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2012, 36 : 395A - 395A
  • [10] Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade
    Gavva, Narender R.
    Bannon, Anthony W.
    Hovland, David N., Jr.
    Lehto, Sonya G.
    Klionsky, Lana
    Surapaneni, Sekhar
    Immke, David C.
    Henley, Charles
    Arik, Leyla
    Bak, Annette
    Davis, James
    Ernst, Nadia
    Hever, Gal
    Kuang, Rongzhen
    Shi, Licheng
    Tamir, Rami
    Wang, Jue
    Wang, Weiya
    Zajic, Gary
    Zhu, Dawn
    Norman, Mark H.
    Louis, Jean-Claude
    Magal, Ella
    Treanor, James J. S.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 323 (01): : 128 - 137